- Home
- CRDO vs NBIX Comparison
CRDO vs NBIX Comparison
Compare CRDO & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDO
- NBIX
- Stock Information
- Founded
- CRDO 2008
- NBIX 1992
- Country
- CRDO Cayman Islands
- NBIX United States
- Employees
- CRDO N/A
- NBIX N/A
- Industry
- CRDO Semiconductors
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDO Technology
- NBIX Health Care
- Exchange
- CRDO Nasdaq
- NBIX Nasdaq
- Market Cap
- CRDO 7.8B
- NBIX 11.6B
- IPO Year
- CRDO 2022
- NBIX 1996
- Fundamental
- Price
- CRDO $44.70
- NBIX $109.03
- Analyst Decision
- CRDO Strong Buy
- NBIX Buy
- Analyst Count
- CRDO 10
- NBIX 21
- Target Price
- CRDO $71.40
- NBIX $166.60
- AVG Volume (30 Days)
- CRDO 7.2M
- NBIX 1.3M
- Earning Date
- CRDO 03-04-2025
- NBIX 04-30-2025
- Dividend Yield
- CRDO N/A
- NBIX N/A
- EPS Growth
- CRDO N/A
- NBIX 33.20
- EPS
- CRDO 0.03
- NBIX 3.29
- Revenue
- CRDO $327,532,000.00
- NBIX $2,355,300,000.00
- Revenue This Year
- CRDO $106.05
- NBIX $16.08
- Revenue Next Year
- CRDO $57.02
- NBIX $15.87
- P/E Ratio
- CRDO $1,541.33
- NBIX $33.09
- Revenue Growth
- CRDO 99.38
- NBIX 24.81
- 52 Week Low
- CRDO $16.82
- NBIX $105.18
- 52 Week High
- CRDO $86.69
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- CRDO 39.14
- NBIX 30.69
- Support Level
- CRDO $38.70
- NBIX $105.18
- Resistance Level
- CRDO $47.58
- NBIX $115.31
- Average True Range (ATR)
- CRDO 5.55
- NBIX 3.26
- MACD
- CRDO -0.88
- NBIX -0.04
- Stochastic Oscillator
- CRDO 27.84
- NBIX 22.63
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.